Snippets - 2

Analysis of emotional fluctuations in infertile women during ART treatment: the impact of ovarian hyperstimulation (Zhou X, Liang S, Ji D, Liang C, Cao Y. Analysis of emotional fluctuations in infertile women during ART treatment: The impact of ovarian hyperstimulation. J Psychosom Obstet Gynaecol 2025;46:1-13). Infertility and use of assisted reproductive technique (ART) for its treatment is increasing globally. Use of ART and resultant ovarian hyperstimulation syndrome (OHSS) is associated with emotional and psychological impact. This single-center longitudinal study in China included 1429 women undergoing their first ART cycle. The psychological state of participants was assessed, before ART, postsurgery (early pregnancy), midpregnancy, and late pregnancy using four validated scales to measure anxiety, depression, stress, and sleep quality. Results: Anxiety and depression were peaked postsurgery and then decreased but again increased slightly in late pregnancy. Stress scores decremental while sleep score better during pregnancy period. The generalizing estimation equation model analysis revealed significant dynamic changes in emotional and sleep outcomes across different time points. OHSS occurred in 9.2% of participants, and it amplifies anxiety and stress, warranting integrated psychological support within ART programs, particularly for OHSS-affected women. A Hospital-based perspective observational study on medication-related problems in clinical practice (Dave DR, Patel JA, Suthar JV. A hospital-based perspective observational study on medication-related problems in clinical practice. Indian J Med Spec 2025;16:130-6). Medication-related problem (MRP) is a big issue worldwide. This longitudinal single-center study was done in Gujarat, India. In this study, 195 adult hospitalized patients were evaluated. Types of MRPs were checked based on indications, safety, effectiveness, compliance, and medication errors. The categories of MRP and subdomain MRP details, along with patient compliance and risk factors (polypharmacy, geriatrics, chronic disease, obesity, allergies, and past medical history [PMH]), were evaluated. Study coated prevalence of MRP as 24.61%, with major amongst them were prescribing error (42, 89.3%) and unnecessary drug therapy (35,81.3%). MRPs show a strong correlation between chronic disease and polypharmacy in statistical analysis and network graph. Identification of potential biomarkers and pathways related to major depressive disorder by integrated bioinformatic analysis and experimental validation (Zeng Y, Peng LQ, Zhang M, Zhong R, Nie KC, Huang W. Identification of potential biomarkers and pathways related to major depressive disorder by integrated bioinformatic analysis and experimental validation. Asian Pac J Trop Biomed 2025;15:200-9). Major depressive disorder (MDD) is a complex psychiatric condition characterized by persistent low mood, lack of motivation, disruptions in sleep and appetite, cognitive impairments, and, in severe cases, suicidal ideation. A genetic predisposition is also known to contribute to its pathophysiology. In this study, three publicly available gene expression datasets comprising a total of 203 individuals (103 patients diagnosed with MDD and 100 healthy controls) were obtained from the Gene Expression Omnibus database. From these datasets, 658 differentially expressed genes (DEGs) were identified using the criteria of P < 0.05 and log₂ fold change (log₂FC) >0, indicating significant expression differences between MDD and control samples. To elucidate the biological significance of the DEGs, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed. In addition, a protein–protein interaction network and weighted gene coexpression network analysis were constructed to identify key signaling pathways and hub gene modules associated with MDD. Subsequently, the expression levels of five candidate hub genes, GRB2, TLR2, SOCS1, PTK2B, and MAPK14, were validated in the hippocampal tissue of a depression-like rat model using reverse transcription-polymerase chain reaction and western blotting. This study identifies GRB2, TLR2, SOCS1, PTK2B, and MAPK14 as potential hub genes implicated in the pathogenesis of MDD, suggesting that therapeutic targeting of these genes may represent a promising strategy for the treatment of MDD. Hearing aid service models, technology, and patient outcomes: A randomized clinical trial (Wu YH, Stangl E, Branscome K, Oleson J, Ricketts T. Hearing aid service models, technology, and patient outcomes: A randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2025;151:423-4). Hearing loss is a global health concern. The high cost of hearing aids (HAs) limits their adoption, and to justify the cost, better outcomes are expected from higher-end HAs. A study was conducted to determine the effect of HA service delivery models and technology levels on patient outcomes. This randomized clinical trial included 245 patients over 55 years of age with mild-to-moderate hearing loss and no previous HA experience. Participants were randomly assigned to one of the six parallel groups, representing a factorial combination of three service delivery models, such as audiologist-fitted (AUD), over-the-counter (OTC), and a hybrid OTC + model, and two technology levels (high-end and low-end HAs). Outcomes were assessed using the Glasgow Hearing Aid Benefit Profile (GHABP), administered through Ecological Momentary Assessment (EMA). EMA-GHABP data were collected preintervention and throughout the 7th week postintervention. The results showed that the global EMA-GHABP score for the AUD group was significantly higher than those for the OTC + and OTC groups, indicating better outcomes with audiologist-fitted HAs. There was no significant difference in outcomes between high-end and low-end HAs. FDA approves first gene therapies to treat patients with sickle cell disease: (Available from:https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. [Last accessed on 2025 May 20). The US Food and Drug Administration (FDA) has approved two landmark cell-based gene therapies, Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), for the treatment of sickle cell disease (SCD) in patients aged 12 years and older. These approvals represent a significant advancement in the field of genomic medicine. Casgevy is the first FDA-approved therapeutic utilizing CRISPR/Cas9 genome editing technology. CRISPR/Cas9 functions as a precise molecular tool capable of introducing site-specific double-stranded breaks in DNA. This enables targeted modifications, such as insertion, deletion, or replacement of genetic sequences, at defined genomic loci. In the case of Casgevy, autologous hematopoietic stem and progenitor cells (HSPCs) are harvested from the patient, and CRISPR/Cas9 is employed ex vivo to disrupt the BCL11A erythroid-specific enhancer. This modification reactivates the expression of fetal hemoglobin (HbF), which inhibits hemoglobin polymerization and prevents sickling of red blood cells. The edited HSPCs are then reinfused into the patient following myeloablative conditioning, where they engraft in the bone marrow and restore hematopoiesis with elevated HbF levels. Lyfgenia employs a lentiviral vector-based gene addition strategy to modify autologous HSPCs. The lentiviral vector delivers a transgene encoding HbAT87Q, a modified form of the β-globin protein that mimics the function of normal adult hemoglobin (HbA) when being resistant to sickling. Following transduction, the genetically modified HSPCs are infused back into the patient, where they engraft and differentiate into erythroid cells capable of expressing the therapeutic hemoglobin variant. These gene therapies offer a potentially curative approach to SCD by addressing the underlying genetic cause and restoring effective erythropoiesis. Their approval marks a paradigm shift in the treatment of hemoglobinopathies and underscores the transformative potential of genomic and cell-based therapies in clinical medicine. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.